References

1. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, et al. (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112. View
2. Jabbour SA, Goldstein BJ (2008) Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 62: 1279-1284. View
3. Clar C, Gill JA, Court R, Waugh N (2012) Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2. View
4. Musso G, Gambino R, Cassader M, Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44: 375-393. View
5. Yanai H, Katsuyama H, Hamasaki H, Adachi H, Moriyama S, et al. (2016) Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering. J Clin Med Res 8: 10-14. View
6. Scheen AJ, Paquot N (2014) Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 40: S4-4S11. View
7. Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, et al. (2012) Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55: 7828-7840. View